| Hematology | Lifetime | 32 | US 23 | 99.82 |
| Internal Medicine | Lifetime | 24 | US 5 | 99.43 |
| Immunology | Lifetime | 667 | US 341 | 97.95 |
| Cancer Research | Lifetime | 433 | US 231 | 97.37 |
| Medical Genetics | Lifetime | 350 | US 179 | 97.05 |
| Immunology and Allergy | Lifetime | 680 | US 281 | 85.94 |
| Internal Medicine | 2021-2025 | 20 | US 8 | 97.68 |
| Hematology | 2021-2025 | 135 | US 64 | 96.56 |
| Molecular Biology | 2021-2025 | 823 | US 227 | 95.49 |
| Infectious Diseases | 2021-2025 | 303 | US 123 | 94.37 |
| Immunology | 2021-2025 | 382 | US 140 | 89.53 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 964 | US 427 | 78.91 |
| Medical Genetics | 2021-2025 | 355 | US 165 | 74.50 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 3 | US 1 | 99.87 |
| Venous Thromboembolism Diagnosis and Management | Lifetime | 15 | US 8 | 99.88 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 19 | US 11 | 99.58 |
| Extracellular vesicles in disease | Lifetime | 29 | US 12 | 99.51 |
| Hemophilia Treatment and Research | Lifetime | 11 | US 4 | 99.47 |
| Platelet Disorders and Treatments | Lifetime | 39 | US 16 | 99.44 |
| COVID-19 Clinical Research Studies | Lifetime | 188 | US 48 | 99.05 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 40 | US 13 | 98.42 |
| Cell Adhesion Molecules Research | Lifetime | 209 | US 114 | 99.20 |
| Protease and Inhibitor Mechanisms | Lifetime | 118 | US 59 | 98.95 |
| Immune Response and Inflammation | Lifetime | 368 | US 178 | 99.03 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 225 | US 97 | 98.85 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 177 | US 90 | 98.24 |
| NF-κB Signaling Pathways | Lifetime | 228 | US 95 | 97.66 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 531 | US 234 | 97.29 |
| Inflammasome and immune disorders | Lifetime | 405 | US 118 | 96.24 |
| Nuclear Receptors and Signaling | Lifetime | 265 | US 125 | 96.14 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 896 | US 334 | 94.96 |
| Escherichia coli research studies | Lifetime | 799 | US 299 | 94.64 |
| Phagocytosis and Immune Regulation | Lifetime | 658 | US 265 | 91.80 |
| Apelin-related biomedical research | Lifetime | 551 | US 165 | 88.74 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 615 | US 234 | 90.00 |
| Dermatological and COVID-19 studies | Lifetime | 433 | US 117 | 83.78 |
| Macrophage Migration Inhibitory Factor | Lifetime | 817 | US 326 | 82.14 |
| Inflammation biomarkers and pathways | Lifetime | 770 | US 199 | 72.12 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 5 | US 2 | 98.99 |
| Venous Thromboembolism Diagnosis and Management | 2021-2025 | 43 | US 18 | 99.26 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 10 | US 4 | 97.55 |
| COVID-19 Clinical Research Studies | 2021-2025 | 434 | US 115 | 98.01 |
| Extracellular vesicles in disease | 2021-2025 | 246 | US 27 | 95.92 |
| Inflammasome and immune disorders | 2021-2025 | 149 | US 31 | 94.01 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 89 | US 8 | 93.03 |
| Platelet Disorders and Treatments | 2021-2025 | 142 | US 32 | 95.45 |
| Immune Response and Inflammation | 2021-2025 | 278 | US 72 | 87.79 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 566 | US 108 | 88.47 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 84 | US 5 | 80.16 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 442 | US 87 | 83.70 |
| Cell Adhesion Molecules Research | 2021-2025 | 648 | US 169 | 73.65 |
| Hemophilia Treatment and Research | 2021-2025 | 472 | US 113 | 78.58 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 553 | US 84 | 66.13 |
